STOCK TITAN

Journey Medical (DERM) CEO granted RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Journey Medical Corp reported that President & CEO Claude Maraoui received new equity awards as part of his compensation. On April 22, 2026, he was granted 49,277 restricted stock units that vest in three equal annual installments from 2027 through 2029.

He was also granted stock options for 82,915 shares at an exercise price of $5.04 per share, vesting on the same 2027–2029 schedule and expiring in 2036. Following these grants, Maraoui directly holds 2,435,990 shares of common stock and 82,915 options.

Positive

  • None.

Negative

  • None.
Insider Maraoui Claude
Role President & CEO
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 82,915 $0.00 --
Grant/Award Common Stock, $0.0001 par value 49,277 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 82,915 shares (Direct, null); Common Stock, $0.0001 par value — 2,435,990 shares (Direct, null)
Footnotes (1)
  1. On April 22, 2026, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on April 22, 2027, 16,426 shares on April 22, 2028 and 16,425 shares on April 22, 2029. Includes restricted stock units, which vest over various time periods. On April 22, 2026, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on April 22, 2027, 27,638 shares on April 22, 2028 and 27,639 shares on April 22, 2029.
RSUs granted 49,277 units Restricted stock units granted on April 22, 2026
RSU vesting schedule 2027 16,426 units Vest on April 22, 2027
RSU vesting schedule 2028 16,426 units Vest on April 22, 2028
RSU vesting schedule 2029 16,425 units Vest on April 22, 2029
Stock options granted 82,915 options Granted on April 22, 2026
Option exercise price $5.04 per share Exercise price for 82,915 options
Option expiration April 22, 2036 Expiration date of granted options
Shares held after grant 2,435,990 shares Common stock directly owned after April 22, 2026 grant
restricted stock units financial
"the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
2015 Stock Plan financial
"pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest"
vesting financial
"that will vest in accordance with the following schedule: 16,426 shares on April 22, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
par value financial
"Common Stock, $0.0001 par value"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maraoui Claude

(Last)(First)(Middle)
C/O JOURNEY MEDICAL CORPORATION
9237 E VIA DE VENTURA BLVD., SUITE 105

(Street)
SCOTTSDALE ARIZONA 85258

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $0.0001 par value04/22/2026A49,277(1)A$02,435,990(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.0404/22/2026A82,915 (3)04/22/2036Common Stock, $0.0001 par value82,915$082,915D
Explanation of Responses:
1. On April 22, 2026, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on April 22, 2027, 16,426 shares on April 22, 2028 and 16,425 shares on April 22, 2029.
2. Includes restricted stock units, which vest over various time periods.
3. On April 22, 2026, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on April 22, 2027, 27,638 shares on April 22, 2028 and 27,639 shares on April 22, 2029.
/s/ Ramsey Alloush, attorney-in-fact04/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Journey Medical (DERM) report for Claude Maraoui?

Journey Medical reported that President & CEO Claude Maraoui received equity compensation, including 49,277 restricted stock units and 82,915 stock options. These awards were granted on April 22, 2026 under the company’s 2015 Stock Plan, reflecting routine executive incentive grants rather than open-market trades.

How many restricted stock units did the Journey Medical (DERM) CEO receive?

Claude Maraoui received 49,277 restricted stock units. According to the grant terms, 16,426 units vest on April 22, 2027, another 16,426 vest on April 22, 2028, and the remaining 16,425 vest on April 22, 2029, subject to plan conditions being satisfied.

What stock options were granted to the Journey Medical (DERM) CEO?

Maraoui was granted stock options for 82,915 shares of Journey Medical common stock at an exercise price of $5.04 per share. These options vest in three annual tranches from 2027 to 2029 and expire on April 22, 2036, providing long-term equity-based compensation.

When do the new Journey Medical (DERM) CEO equity awards vest?

Both the restricted stock units and stock options granted on April 22, 2026 vest over three years. RSUs and options vest in tranches on April 22, 2027, April 22, 2028, and April 22, 2029, aligning the CEO’s incentives with multi-year company performance.

How many Journey Medical (DERM) shares does the CEO hold after these grants?

After the April 22, 2026 transactions, Claude Maraoui directly holds 2,435,990 shares of Journey Medical common stock. In addition, he holds 82,915 stock options linked to the same common stock, giving him both current ownership and potential future share rights.

Are the Journey Medical (DERM) CEO’s new awards open-market purchases or compensation grants?

The Form 4 shows these are compensation-related grants, not open-market trades. Both the 49,277 restricted stock units and the 82,915 stock options are classified as awards under the company’s 2015 Stock Plan, with no purchase price paid per share at grant.